Literature DB >> 4683071

Pharmacology of orally administered 9 -tetrahydrocannabinol.

M Perez-Reyes, M A Lipton, M C Timmons, M E Wall, D R Brine, K H Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4683071     DOI： 10.1002/cpt197314148

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  22 in total

1.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-01-11       Impact factor: 4.492

Review 4.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

5.  Subjective and behavioral effects of marijuana the morning after smoking.

Authors:  L D Chait
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Marijuana advertising exposure among current marijuana users in the U.S.

Authors:  Melissa J Krauss; Shaina J Sowles; Auriann Sehi; Edward L Spitznagel; Carla J Berg; Laura J Bierut; Patricia A Cavazos-Rehg
Journal:  Drug Alcohol Depend       Date:  2017-03-29       Impact factor: 4.492

7.  Intercannabinoid and cannabinoid-ethanol interactions on human performance.

Authors:  K D Bird; T Boleyn; G B Chesher; D M Jackson; G A Starmer; R K Teo
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

8.  Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

Authors:  Tsadik T Abraham; Ross H Lowe; Stephane O Pirnay; William D Darwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-10       Impact factor: 3.367

9.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

10.  The oral activity of delta'-tetrahydrocannabinol and its dependence on prostaglandin E2.

Authors:  J W Fairbairn; J T Pickens
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.